Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user is considering starting Minoxidil and is looking for a topical solution to combine with it. They are confused about which product to prioritize among options like RU58841, Pyrilutamide, FinaTopic, and DutaTopic.

Eucapil (fluridil) may reduce hair shedding. It can be added to a regimen with finasteride and minoxidil.

The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.

The conversation discusses the effectiveness of finasteride and microneedling for treating hair loss. The linked article is seen as an advertisement for these treatments.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

Using a combination of topical finasteride, minoxidil, caffeine and dermaroller treatments to help with hair loss, while discussing the potential results and other options.

Finasteride is being considered for purchase in Turkey due to cheaper prices and availability compared to Hungary and Poland. The user seeks information on over-the-counter availability, pricing, and reliable pharmacies in Istanbul.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.

The conversation is about a person's hair regrowth after 100 days using finasteride (0.5mg), minoxidil (3mg), and dermarolling, with others noticing improvement and discussing the appearance of the scalp and hairline.

Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.

The conversation is a satirical discussion about using a dermaroller on the penis, with mentions of adding finasteride and doing exercises like cock pushups and planks. Some users joke about side effects and the absurdity of the topic.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

Using a combination of finasteride, minoxidil, dermarolling, and RU58841 to treat hair loss. Participants discussed the time commitment required for treatment and the effectiveness of different dosages.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

Dutasteride once a week may be a cost-effective alternative to daily finasteride for reducing DHT levels, with potential benefits for those seeking a lighter approach to hair loss treatment. Some users combine dutasteride with finasteride, minoxidil, and dermarolling for improved results.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The user is considering switching their hair loss routine from taking finasteride daily to a combination of finasteride six times a week and dutasteride once a week. They are seeking advice on this potential change.